NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
Clinical Trials
65 trialsNCT04773782 2026-01-13
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Blueprint Medicines Corporation
Phase 1/2 Completed
NCT01478178 2025-08-29
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Kintara Therapeutics, Inc.
Phase 1/2 Completed
NCT02655601 2025-06-08
BMX-HGG
BioMimetix JV, LLC
Phase 1/2 Completed
NCT02311582 2025-05-29
MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Washington University School of Medicine
Phase 1/2 Completed
NCT02960230 2025-01-22
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
University of California, San Francisco
Phase 1/2 Completed
NCT04267146 2024-12-02
NIVOGLIO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Completed
NCT03234595 2024-09-19
A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
Everfront Biotech Co., Ltd.
Phase 1/2 Completed
NCT03879512 2024-09-19
Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG
Wuerzburg University Hospital
Phase 1/2 Completed
NCT06562621 2024-08-20
Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma
Beijing Neurosurgical Institute
Phase 1/2 Completed
NCT04497142 2024-08-05
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01837862 2024-07-05
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Northwell Health
Phase 1/2 Completed
NCT02490800 2024-06-26
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
Basilea Pharmaceutica
Phase 1/2 Completed
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT01128218 2023-11-30
A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors
Southern Illinois University
Phase 1/2 Completed
NCT02315534 2023-11-15
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT03245151 2023-08-30
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Eisai Inc.
Phase 1/2 Completed
NCT02661282 2023-06-18
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01081223 2023-06-01
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVAX Biomedical
Phase 1/2 Completed
NCT01792310 2023-02-21
A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours
Laminar Pharmaceuticals
Phase 1/2 Completed
NCT02330562 2022-06-08
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
Phase 1/2 Completed
NCT02750891 2022-04-12
A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
Sumitomo Pharma Co., Ltd.
Phase 1/2 Completed
NCT00303849 2022-03-17
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
OHSU Knight Cancer Institute
Phase 1/2 Completed
NCT01051557 2021-07-19
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02273739 2021-02-23
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Celgene
Phase 1/2 Completed
NCT01024907 2020-12-10
Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT02590263 2020-09-03
Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
AbbVie
Phase 1/2 Completed
NCT02496741 2020-01-09
MACIST
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Completed
NCT00049127 2019-10-21
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT01454596 2019-08-21
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01580969 2019-08-16
RAMBO
University of Utah
Phase 1/2 Completed
NCT00038441 2018-10-31
Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01977677 2018-10-23
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Stanford University
Phase 1/2 Completed
NCT02253212 2018-10-12
SONOCLOUD
Assistance Publique - Hôpitaux de Paris
Phase 1/2 Completed
NCT01266031 2018-07-31
Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00003616 2018-06-27
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00004868 2018-06-27
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00010049 2018-06-27
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00022724 2018-06-26
CCI-779 in Treating Patients With Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT01648348 2018-05-23
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00766753 2018-02-07
Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
University of Pittsburgh
Phase 1/2 Completed
NCT01465347 2017-07-14
Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
Diffusion Pharmaceuticals Inc
Phase 1/2 Completed
NCT01026493 2017-07-02
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT01290263 2017-07-02
Amgen 386 for Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01125800 2017-03-20
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Novartis
Phase 1/2 Completed
NCT00859222 2017-03-14
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01220271 2017-02-16
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
Eli Lilly and Company
Phase 1/2 Completed
NCT02104882 2016-10-17
INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study
Universitätsmedizin Mannheim
Phase 1/2 Completed
NCT00250211 2016-02-24
Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide
AHS Cancer Control Alberta
Phase 1/2 Completed
NCT00124657 2015-12-04
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
St. Jude Children's Research Hospital
Phase 1/2 Completed